|« Previous month||Next month »|
29-Aug-2013 - ICIG will buy the Belgian operation of peptide maker Peptisyntha SA from Solvay to expand its recently rejigged contract API business.
29-Aug-2013 - Being pipped to the post by the cast of Sesame St is rarely a positive, but when it means in-Pharmatechnologist.com's tech team has the time to develop an iPhone App as good...
29-Aug-2013 - Many physicians would switch migraine patients from oral treatments if the same drugs were available as a nasal inhalation, topical, or transdermal patch according to a new report.
28-Aug-2013 - The US FDA has released a Q&A to offer more clarity to GPhA, Cipla, Akorn and other drug and API manufacturers who responded to the initial stability draft guidance for...
28-Aug-2013 - Amgen spent $10.4bn (€7.8bn) this week on Onyx Pharmaceuticals, but AstraZeneca and Johnson & Johnson have also opened up their wallets this week – welcome to in-Pharmatechnologist.com’s merger & acquisition...
28-Aug-2013 - Eisai has become the first London Declaration signatory to be pre-qualified to make treatments for neglected tropical diseases by the WHO.
28-Aug-2013 - Dust is rubbish, literally. And in a pharmaceutical plant it can also put employee health in danger and be the cause of product recalls.
27-Aug-2013 - Aoxing Pharmaceuticals reported increased sales and lower operating expenses for Q2 2013 one year on from the chromatin-tainted gelatin scandal that led to suspension of sales by China’s regulators.
27-Aug-2013 - Amarin wants US regulatory approval to add Novasep to the list of APIs suppliers for its fish oil heart pill, Vascepa.
27-Aug-2013 - EFPIA has backed MHRA plans to inspect API imports at manufacturing plants rather than at UK borders.
26-Aug-2013 - IMCD Group will promote APIs made by Italian firm FIS in territories in Eastern Europe and the Southern hemisphere under a new agreement.
26-Aug-2013 - Novo Nordisk's North American affiliate has a new President and more news from drug delivery firm Enteris - welcome to in-Pharmatechnologist.com' People on the Move.
26-Aug-2013 - Amgen has spent $10.4bn (€7.8bn) in acquiring Onyx Pharmaceuticals saying its oncology products and pipeline will be strengthened by Amgen’s manufacturing capabilities.
26-Aug-2013 - Swiss API manufacturer Siegfried reported that higher API sales and custom synthesis orders drove a profit increase in the first half of the year and predicted that recent capacity hike...
22-Aug-2013 - Description of the manufacturing process in regulatory submissions must be the same whether the applicants use Quality by Design (QbD) or the traditional approach, the FDA and EMA have concluded.
22-Aug-2013 - Jubilant HollisterStier (JHS) says expansion of its sterile manufacturing capacity at its facility in Kirkland, Canada will be used to fulfill several new contracts.
22-Aug-2013 - Pfizer has remained the world’s largest public manufacturer of pharmaceuticals, according to an industry report, though dropped revenue in 2012 has left Novartis hot on its heels.
21-Aug-2013 - The MHRA says it will assess the quality of active pharmaceutical ingredients (APIs) imported from outside the EU at manufacturers’ facilities rather than at UK borders.
21-Aug-2013 - NanoViricides' nanotech drug delivery platform has the potential to eliminate viruses, the firm says as construction began on a manufacturing facility to support upcoming clinical trials.
20-Aug-2013 - Fresenius Kabi will focus on intravenous generics and infusion solutions as it acquires a 51 percent stake in an Indonesian pharma company.
20-Aug-2013 - The two-year pilot project will help the US Food and Drug Administration further assess the growing number of companies and countries involved in importing drugs to the US.
19-Aug-2013 - The TransCelerate BioPharma industry group has launched its clinical trial comparator network to establish a reliable means for sourcing quality drugs for clinical trials.
19-Aug-2013 - Mannkind says it is looking for partners to market its inhaled insulin drug Afrezza following positive data results in Phase III clinical trials.
19-Aug-2013 - Codexis has denied breaching its licensing deal with Dyadic International and says losing rights to the C1 fungal expression system would hit its CodeXyme business hard.
|« Previous month||Next month »|